Journal Articles

Bedaquiline for multidrug-resistant TB in paediatric patients

2022-09-26T16:34:37+02:0012 May 2021|

THINK’s first paediatric study, sponsored by Janssen Pharmaceuticals, started in May 2015 headed by Dr Ronelle Moodliar at the King Dinuzulu clinical trial site. The study was supported by Seshni Moorgas as the trial coordinator together with Nokuthula Ngcobo and Lungile Phakatias the research nurses. The study contributed towards more than 50% of the total recruited patients globally for cohorts 1 and 2 (>5 to <18 years) and is currently enrolling children into the >2 to <5-year cohort. Through the successful achievements of this study thus far, the paediatric dosage and formulation for the age groups of 5-18-years have now [...]

Health system determinants of tuberculosis mortality in South Africa: a causal loop model

2022-09-26T18:29:00+02:0026 April 2021|

Published: 26 April 2021 Authors: Muhammad Osman, Aaron S Karat, Munira Khan, Sue-Ann Meehan, Arne von Delft, Zameer Brey, Salome Charalambous, Anneke C Hesseling, Pren Naidoo & Marian Loveday Journal: BMC Health Services Research 21, Article number: 388 (2021) ABSTRACT Background: Tuberculosis (TB) is a major public health concern in South Africa and TB-related mortality remains unacceptably high. Numerous clinical studies have examined the direct causes of TB-related mortality, but its wider, systemic drivers are less well understood. Applying systems thinking, we aimed to identify factors underlying TB mortality in South Africa and describe their relationships. At a meeting organised [...]

A narrative systematic review of tobacco cessation interventions in Sub-Saharan Africa

2022-09-26T16:23:53+02:0029 May 2020|

Published: 29 May 2020Authors: Nasheeta Peer1,2 , Ashika Naicker3 , Munira Khan4 and Andre-Pascal Kengne1,2Journal: SAGE Open Medicine Volume 8: 1–12ABSTRACTAim: In the face of increasing tobacco consumption in Sub-Saharan Africa, it is crucial to not only curb the uptake of tobacco, but to ensure that tobacco users quit. Considering the minimal attention that tobacco cessation interventions receive in Sub- Saharan Africa, this review aims to describe studies that evaluated tobacco cessation interventions in the region.Methods: A search of studies published till December 2019 that evaluated tobacco cessation interventions in Sub-Saharan Africa and examined tobacco quit rates was conducted in PubMed-Medline, [...]

Community-based care vs. centralised hospitalisation for MDRTB patients, KwaZulu-Natal, South Africa

2022-09-26T16:20:31+02:001 February 2015|

Date: 1 February 2015 Authors: Loveday, M. 1 ; Wallengren, K. 2; Brust, J. 3 ; Roberts, J. 4; Voce, A. 5 ; Margot, B. 6 ; Ngozo, J. 6 ; Master, I. 7 ; Cassell, G. 8 ; Padayatchi, N. 9 ; Publisher: International Union Against Tuberculosis and Lung Disease ABSTRACT: SETTING: KwaZulu-Natal, South Africa, a predominantly rural province with a high burden of tuberculosis (TB), multidrug-resistant TB (MDR-TB) and human immunodeficiency virus (HIV) infection. OBJECTIVE: To determine the most effective care model by comparing MDR-TB treatment outcomes at community-based sites with traditional care at a central, specialised hospital. DESIGN: [...]

Drug-Resistant Tuberculosis, KwaZulu-Natal, South Africa, 2001–2007

2022-09-26T16:08:12+02:001 February 2015|

Date: October, 2011 Authors: Kristina Wallengren, Fabio Scano, Paul Nunn, Bruce Margot, Sandile S.S. Buthelezi, Brian Williams, Alexander Pym, Elisabeth Y. Samuel, Fuad Mirzayev, Wilfred Nkhoma, Lindiwe Mvusi, and Yogan Pillay Publisher: Emerging Infectious Diseases ABSTRACT: In Africa, incidence and prevalence of drug-resistant tuberculosis have been assumed to be low. However, investigation after a 2005 outbreak of extensively drug-resistant tuberculosis in KwaZulu-Natal Province, South Africa, found that the incidence rate for multidrug-resistant tuberculosis in KwaZulu-Natal was among the highest globally and would be higher if case-finding efforts were intensified. Keywords: XDR TB, MDR TB, outbreak, South Africa, incidence, tuberculosis, antimicrobial [...]

Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa

2022-09-28T13:45:04+02:001 February 2012|

Date: 1 February 2012 Authors: Loveday, M. 1 ; Wallengren, K. 2 ; Voce, A. 3 ; Margot, B. 4 ; Reddy, T.5 ; Master, I. 4 ; Brust, J. 6 ; Chaiyachati, K. 7; Padayatchi, N. 8 ; Publisher: International Union Against Tuberculosis and Lung Disease SETTING: In KwaZulu-Natal, South Africa, a setting endemic for tuberculosis (TB) and the human immunodeficiency virus (HIV), prolonged hospitalisation for the treatment of the growing number of multidrug-resistant TB (MDR-TB) patients is neither possible nor effective. OBJECTIVE: To compare early treatment outcomes in patients with MDR-TB with and without HIV coinfection at four decentralised [...]

Resistance to TB drugs in KwaZulu-Natal causes and prospects for control

2022-09-26T16:17:09+02:009 July 2011|

Date: 9 July 2011 Authors: Wallengren,1* F. Scano,2 P. Nunn,2 B. Margot,3 S. Buthelezi,3 B. Williams,4 A. Pym,5 E. Y. Samuel,6 F. Mirzayev,2 W. Nkhoma7, L. Mvusi,8 and Y. Pillay8 Abstract: Background: In 2005 there was an outbreak of XDR (extensively drug resistant) TB in Tugela Ferry, which is served by the Church of Scotland Hospital (COSH), in the uMzinyathi District, KwaZulu-Natal, South Africa. An investigation was carried out to determine if XDR TB was occurring elsewhere in the province, and to develop hypotheses for the rise in drug resistance with a view to developing a strategy for the control of [...]

Go to Top